Is hydroxychloroquine beneficial for COVID-19 patients?

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world(1–3), the World Health Organization (WHO) declared a public health emergency of internatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xing, Wang, Ying, Agostinis, Patrizia, Rabson, Arnold, Melino, Gerry, Carafoli, Ernesto, Shi, Yufang, Sun, Erwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341710/
https://www.ncbi.nlm.nih.gov/pubmed/32641681
http://dx.doi.org/10.1038/s41419-020-2721-8
_version_ 1783555291890057216
author Li, Xing
Wang, Ying
Agostinis, Patrizia
Rabson, Arnold
Melino, Gerry
Carafoli, Ernesto
Shi, Yufang
Sun, Erwei
author_facet Li, Xing
Wang, Ying
Agostinis, Patrizia
Rabson, Arnold
Melino, Gerry
Carafoli, Ernesto
Shi, Yufang
Sun, Erwei
author_sort Li, Xing
collection PubMed
description The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world(1–3), the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 2020(4). The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir(5), to control the disease and halt the pandemic.
format Online
Article
Text
id pubmed-7341710
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73417102020-07-08 Is hydroxychloroquine beneficial for COVID-19 patients? Li, Xing Wang, Ying Agostinis, Patrizia Rabson, Arnold Melino, Gerry Carafoli, Ernesto Shi, Yufang Sun, Erwei Cell Death Dis Perspective The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world(1–3), the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 2020(4). The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir(5), to control the disease and halt the pandemic. Nature Publishing Group UK 2020-07-08 /pmc/articles/PMC7341710/ /pubmed/32641681 http://dx.doi.org/10.1038/s41419-020-2721-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Perspective
Li, Xing
Wang, Ying
Agostinis, Patrizia
Rabson, Arnold
Melino, Gerry
Carafoli, Ernesto
Shi, Yufang
Sun, Erwei
Is hydroxychloroquine beneficial for COVID-19 patients?
title Is hydroxychloroquine beneficial for COVID-19 patients?
title_full Is hydroxychloroquine beneficial for COVID-19 patients?
title_fullStr Is hydroxychloroquine beneficial for COVID-19 patients?
title_full_unstemmed Is hydroxychloroquine beneficial for COVID-19 patients?
title_short Is hydroxychloroquine beneficial for COVID-19 patients?
title_sort is hydroxychloroquine beneficial for covid-19 patients?
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341710/
https://www.ncbi.nlm.nih.gov/pubmed/32641681
http://dx.doi.org/10.1038/s41419-020-2721-8
work_keys_str_mv AT lixing ishydroxychloroquinebeneficialforcovid19patients
AT wangying ishydroxychloroquinebeneficialforcovid19patients
AT agostinispatrizia ishydroxychloroquinebeneficialforcovid19patients
AT rabsonarnold ishydroxychloroquinebeneficialforcovid19patients
AT melinogerry ishydroxychloroquinebeneficialforcovid19patients
AT carafoliernesto ishydroxychloroquinebeneficialforcovid19patients
AT shiyufang ishydroxychloroquinebeneficialforcovid19patients
AT sunerwei ishydroxychloroquinebeneficialforcovid19patients

Ejemplares similares